Sign in

Myelodysplastic syndromes: trials that stopped early

Trials on Myelodysplastic syndromes that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

86 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

    Reason given in the registry

    “FDA Clinical Hold”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2026.

    Ended
    Oct 2026
    Phase
    Phase 1
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT02530034
  2. Terminated

    Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

    Reason given in the registry

    “No longer have funding support to complete the pharmacogenetics component.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.

    Ended
    Mar 2025
    Phase
    Phase 2
    Run by
    Medical College of Wisconsin
    Registry record
    NCT03150004
  3. Suspended

    Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

    Reason given in the registry

    “Accrual goal Met”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT03969446
  4. Terminated

    MBG453 in Lower Risk MDS

    Reason given in the registry

    “The trial closed early due to changes in support for the study drug.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.

    Ended
    Nov 2025
    Phase
    Phase 2
    Run by
    Massachusetts General Hospital
    Registry record
    NCT04823624
  5. Suspended

    Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “resources”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT06454409
  6. Suspended

    Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

    Reason given in the registry

    “Timeline Adjustment”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2026.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT06195891
  7. Suspended

    Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

    Reason given in the registry

    “Funding unavailable”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Oct 2026.

    Phase
    Phase 2
    Run by
    Abhay Singh, MD MPH
    Registry record
    NCT06630221
  8. Suspended

    Ascorbate in Myelodysplastic Syndrome

    Reason given in the registry

    “temporary suspension”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Oct 2026.

    Phase
    Phase 2
    Run by
    Prajwal Dhakal
    Registry record
    NCT07283900
  9. Withdrawn

    A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

    Reason given in the registry

    “PI request”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Oct 2026.

    Ended
    Jun 2026
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06597734
  10. Terminated

    Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Reason given in the registry

    “Inability to meet protocol objectives”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Oct 2026.

    Ended
    Aug 2026
    Phase
    Phase 1
    Run by
    Bristol-Myers Squibb
    Registry record
    NCT06419634
  11. Terminated

    RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

    Reason given in the registry

    “RPD2 has been identified”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.

    Ended
    May 2024
    Phase
    Phase 1
    Run by
    Ryvu Therapeutics SA
    Registry record
    NCT04021368
  12. Terminated

    Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Sept 2026.

    Ended
    Sept 2025
    Phase
    Phase 2
    Run by
    Ryvu Therapeutics SA
    Registry record
    NCT06268574
  13. Suspended

    ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

    Reason given in the registry

    “insufficient funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2026.

    Phase
    Phase 2
    Run by
    Leland Metheny
    Registry record
    NCT06680661
  14. Suspended

    Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

    Reason given in the registry

    “Drug Supply Issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Sept 2026.

    Phase
    Phase 1
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT06888323
  15. Terminated

    A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

    Reason given in the registry

    “Futility assessment concluded low likelihood of the trial showing meaningful patient benefit.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Sept 2026.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    Forma Therapeutics, Inc.
    Registry record
    NCT05568225
  16. Terminated

    ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

    Reason given in the registry

    “\<75% participants”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Aug 2026.

    Ended
    Aug 2026
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT02392572
  17. Withdrawn

    Pacritinib With Aza for Upfront Myelodysplastic Syndrome

    Reason given in the registry

    “FDA requested significant changes to the study protocol”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Aug 2026.

    Phase
    Phase 1/2
    Run by
    Thomas Jefferson University
    Registry record
    NCT07387354
  18. Suspended

    DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial

    Reason given in the registry

    “Recruitment on hold with plans to open to accrual again soon.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Aug 2026.

    Phase
    Phase 1
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT06492707
  19. Terminated

    Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

    Reason given in the registry

    “The study was closed due to the end of funding.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Aug 2026.

    Ended
    Jul 2026
    Phase
    Phase 2
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT04994808
  20. Terminated

    A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

    Reason given in the registry

    “Slow participant enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Jul 2026.

    Ended
    Mar 2026
    Phase
    Phase 1
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06021600
  21. Suspended

    Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

    Reason given in the registry

    “Funding Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Jul 2026.

    Phase
    Phase 1/2
    Run by
    Mikkael Sekeres, MD
    Registry record
    NCT04539236
  22. Suspended

    Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

    Reason given in the registry

    “Drugs unavailable”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2026.

    Phase
    Phase 1
    Run by
    David Wald
    Registry record
    NCT05400122
  23. Withdrawn

    A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS

    Reason given in the registry

    “The study has not actually been conducted.”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Jul 2026.

    Phase
    Phase 1/2
    Run by
    Peking Union Medical College Hospital
    Registry record
    NCT06020833
  24. Terminated

    A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia

    Reason given in the registry

    “Insufficient enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Jul 2026.

    Ended
    May 2025
    Run by
    Bristol-Myers Squibb
    Registry record
    NCT07681440
  25. Terminated

    Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

    Reason given in the registry

    “\<75% participation”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Jun 2026.

    Ended
    May 2026
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04550442
  26. Terminated

    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

    Reason given in the registry

    “No longer a research question to answer.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2026.

    Ended
    May 2026
    Run by
    Masonic Cancer Center, University of Minnesota
    Registry record
    NCT01962636
  27. Terminated

    Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

    Reason given in the registry

    “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 May 2026.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT03246906
  28. Suspended

    Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

    Reason given in the registry

    “Others”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2026.

    Phase
    Phase 1/2
    Run by
    Sclnow Biotechnology Co., Ltd.
    Registry record
    NCT03184935
  29. Terminated

    A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

    Reason given in the registry

    “Patient recruitment problems.”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2026.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Aurigene Discovery Technologies Limited
    Registry record
    NCT05607199
  30. Terminated

    Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    Reason given in the registry

    “Adjusted the product development strategy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2026.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    Changchun GeneScience Pharmaceutical Co., Ltd.
    Registry record
    NCT05263271

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.